Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children
暂无分享,去创建一个
R. Rappuoli | S. Black | T. Vesikari | M. Knuf | G. Del Giudice | T. Tsai | G. Della Cioppa | R. Clemens | U. Nicolay
[1] J. Yewdell,et al. MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines , 2011, Science Translational Medicine.
[2] K. To,et al. Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] A. Osterhaus,et al. On the relationship between mean antibody level, seroprotection and clinical protection from influenza. , 2009, Biologicals : journal of the International Association of Biological Standardization.
[4] Andrew J Dunning. A model for immunological correlates of protection. , 2006, Statistics in medicine.
[5] K. Poehling,et al. Change in Recommendation Affects Influenza Vaccinations Among Children 6 to 59 Months of Age , 2004, Pediatrics.
[6] R. Walker,et al. Measuring Antibody Responses to a Live Attenuated Influenza Vaccine in Children , 2004, The Pediatric infectious disease journal.
[7] David Goldblatt,et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. , 2003, Vaccine.
[8] S. Plotkin. Immunologic correlates of protection induced by vaccination , 2001, The Pediatric infectious disease journal.
[9] E. Lewis,et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.
[10] R. Davis,et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. , 2000, The New England journal of medicine.
[11] M. Knuf,et al. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b - PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine , 1996, European Journal of Pediatrics.
[12] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.
[13] L. Hagberg,et al. Antitoxin antibody levels and the outcome of illness during an outbreak of diphtheria among alcoholics. , 1986, Scandinavian journal of infectious diseases.
[14] P. Mäkelä,et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. , 1983, The Journal of infectious diseases.
[15] J P Fox,et al. Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. , 1982, American journal of epidemiology.
[16] C B Hall,et al. Viral shedding patterns of children with influenza B infection. , 1979, The Journal of infectious diseases.
[17] A. S. Beare,et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.
[18] E. H. Lennette,et al. Evaluation of monovalent influenza vaccines. II. Observations during an influenza a-prime epidemic. , 1952, American journal of hygiene.
[19] J. Ipsen,et al. Circulating antitoxin at the onset of diphtheria in 425 patients. , 1946, Journal of immunology.